APOE and hepatocellular carcinoma: As expected, apoE-dp was capable of out-competing HCV binding on the surface of hepatoma cells to a similar degree as the HCV entry inhibitor heparin (Fig. 2E) [25], whereas control peptide (CTRL peptide) had no effect on HCV infection.